Gilead Fixes the Price of COVID-19 Drug Remdesivir; the Government Secures the Bulk of Its Supply
Remdesivir, a malaria drug that has been repurposed to treat COVID-19 and currently represents the best hope for attacking the disease, now has a price tag. On Monday, the company behind the medication, Gilead Sciences (NASDAQ: GILD), said it will be sold at $390 per vial. Therefore, the basic price for a five-day treatment course using six vials would be $2,340.
Gilead added that "[b]ecause of the way the U.S. system is set up and the discounts that government healthcare programs expect," the price for U.S. private insurance companies will be $520 per vial. This equates to $3,120 per treatment course, with the patient's final bill depending on the policy's coverage.
Image source: Gilead Sciences.
Source Fool.com
